Schwamborn K
Institute of Pathology, Technische Universität München (TUM), Munich, Germany.
Adv Cancer Res. 2017;134:1-26. doi: 10.1016/bs.acr.2016.11.001. Epub 2016 Dec 21.
Mass spectrometry imaging (MSI) has become a valuable tool in cancer research. Even more, due to its capability to directly link molecular changes with histology, it holds the prospect to revolutionize tissue-based diagnostics. In order to learn to walk before running, however, information obtained through classical histology should not be neglected but rather used to its full capacity and integrated with mass spectrometry data to lead to a superior molecular histology synthesis. In order to achieve this, pathomorphological analyses have to be integrated into MSI analyses right from the beginning to avoid errors and pitfalls of MSI application possibly leading to incorrect or imprecise study outcomes. Such errors can be caused by different sample or tissue inherent factors or through factors in sample preparation. Future studies should, therefore, aim for a comprehensive incorporation of histology and pathology characteristics to ensure the generation of high-quality data in MSI to exploit its full capacity in tissue-based basic and translational research.
质谱成像(MSI)已成为癌症研究中的一项重要工具。更重要的是,由于其能够直接将分子变化与组织学联系起来,它有望彻底改变基于组织的诊断方法。然而,为了循序渐进,通过传统组织学获得的信息不应被忽视,而应充分利用,并与质谱数据相结合,以实现更卓越的分子组织学综合分析。为了实现这一点,病理形态学分析必须从一开始就融入到MSI分析中,以避免MSI应用中可能导致错误或不精确研究结果的误差和陷阱。这些误差可能由不同的样本或组织固有因素引起,也可能是样本制备过程中的因素导致。因此,未来的研究应致力于全面整合组织学和病理学特征,以确保在MSI中生成高质量的数据,从而在基于组织的基础研究和转化研究中充分发挥其潜力。